Scene 1 (0s)
Business Review. Semester 1 2025/2026. Name: Ramy Al Alfy Title: Date:.
Scene 2 (9s)
YTD-2025/2026 Performance Summary. 2. TOTAL TARGET SEMESTER ACHIEVED ACHEIVEMENT ACHIECED ON Q2 172545 KD 164833 KD 95.5% 105%.
Scene 3 (21s)
YTD-2025/2026 Performance Summary. 3. YTD Budget 25/26 YTD Achievement 25/26 LY Achievement 24/25 % Vs LY Variance Vs LY KOC 25441 7387 6792.76 9% 594.24.
Scene 4 (39s)
YTD-2025/2026 Performance Summary. 4. YTD Budget 25/26 YTD Achievement 25/26 LY Achievement 24/25 % Vs LY Variance Vs LY COOPs 2984 3847.44 2456.21 57% 1391.23.
Scene 5 (59s)
YTD-2025/2026 Performance Per SKU QTY. 5. YTD Achievement 25/26 LY Achievement 24/25 % Bronchicum 145 115 26% Buscopan 3810 5707 -33% Enterogermina Vail 429 546 -21% Mucosolvan Tabs 722 750 -4% Mucosolvan Caps 48 0 4700% Mucosolvan Syr 2561 2334 10% Nasacort 3731 3450 8% Telfast 120mg 15T 220 645 -66% Telfast 120mg 30T 1255 1330 -6% Telfast 180mg 15T 50 175 -71% Telfast T 180mg 30T 4223 4902 -14%.
Scene 6 (1m 21s)
YTD-2025/2026 Performance Summary Per SKU Value. 6.
Scene 7 (1m 52s)
2025/2026 Rx Accounts KOC & KNPC COOPs Trade scattered 41241.83 6378.5 2577.62 91466.32 26040.73.
Scene 8 (2m 10s)
2025/2026 Moasat Al Mangaf Taiba Hospital Hadi Hospital Dar Al Shifaa hospital Alia hospital Nassem Al Jazzera 10991.25 7608.52 4619.8999999999996 11380.5 3245 1270.3 2024/2025 Moasat Al Mangaf Taiba Hospital Hadi Hospital Dar Al Shifaa hospital Alia hospital Nassem Al Jazzera 4991 8938.64 5008.75 14845.15 3895 882.
Scene 9 (2m 32s)
YTD-2025/2026 Performance Top Rx accounts. ALSEEF HOSPITAL YTD Achievement 25/26 LY Achievement 24/25 % Bronchicum Elixir S 100mG 44 0 NASACORT AQ 2592 2587.5 0 TELFAST 120MG. 30 TABS 276 552 -50% TELFAST 180MG. 30 TABS 1925 1925 0 MUCOSOLVAN SYRUP 1010 1010 0 MUCOSOLVAN LA 75 MG. 324 324 0 ENTEROGERMINA VIALS 632.5 418.5 51% BUSCOPAN TAB 810 1215 -33%.
Scene 10 (2m 53s)
YTD-2025/2026 Performance Top Rx accounts. ALSALAM HOSPITAL YTD Achievement 25/26 LY Achievement 24/25 % NASACORT AQ 891 404.25 120% TELFAST 180 30 TABS 2502.5 2310 8% TELFAST 120 30 TABS 1656 552 200% MUCOSOLVAN 75 MG LA 54 0 NEW MUCOSOLVAN SYRUP 404 505 -20% MUCOSOLVAN TABS 154 77 100% BUSCOPAN TABS 480 810 -40% ENTEROGERMINA VIALS NEW.
Scene 11 (3m 11s)
YTD-2025/2026 Performance Top Rx accounts. ALMUWASAT HOSPITAL YTD Achievement 25/26 LY Achievement 24/25 % NASACORT AQ 160 0 100% TELFAST 120 30 TABS 0 552 -100% TELFAST 180 30 TABS 2310 3080 -25% BUSCOPAN TABS 243 324 -25% MUCOSOLVAN SYRUP 505 1010 -50% MUCOSOLVAN TABS 30 0 77 -100% MUCOSOLVAN LA 162 0 +100% ENTEROGERMINA 316.25 116.25 +100%.
Scene 12 (3m 29s)
YTD-2025/2026 Performance Top Rx accounts. ROYAL HAYAT HOSPITAL YTD Achievement 25/26 LY Achievement 24/25 %.
Scene 13 (3m 39s)
Telfast@ Fexofenadine Hydrochloride 120mg : FASTACTINGAUERGYRELIEF 30 tablets ON-DROW 24 Relief of v' Runny Nose Sneezing Itchy, Watery Eyes ltåy Nose orThroat sonofi.
Scene 14 (3m 54s)
2025/2026 KOC KNPC 7387 5370 2024/2025 KOC KNPC 6792.76 3440.
Scene 15 (4m 6s)
YTD-2025/2026 Performance Top Rx accounts. 15. KNPC YTD Achievement 25/26 LY Achievement 24/25 % Bronchicum 1500 0 Buscopan 0 0 Mucosolvan Syr 0 1000 -100% Telfast Tablets 180mg 15T 2500 1500 67%.
Scene 16 (4m 19s)
YTD-2025/2026 Performance Top Rx accounts. 16. KOC YTD Achievement 25/26 LY Achievement 24/25 % Bronchicum 1300 0 #DIV/0! Buscopan 1050 1500 -30% Mucosolvan Syr 0 470 -100% Telfast Tablets 180mg 15T 3400 3278 4%.
Scene 17 (4m 33s)
COOPs. Telfast@ Fexofenadine Hydrochloride 120mg : FASTACTINGAUERGYRELIEF 30 tablets ON-DROW 24 Relief of v' Runny Nose Sneezing Itchy, Watery Eyes ltåy Nose orThroat sonofi.
Scene 18 (4m 48s)
2025/2026 Mishref COOP Zahraa COOP 2577.62 1269.82 2024/2025 Mishref COOP Zahraa COOP 1253.22 625.25.
Scene 19 (5m 1s)
Main Groups.
Scene 20 (5m 13s)
2025/2026 Royal Pharmazone AAW Boots Al Hajerey 76034.61 39300.080000000002 46722.06 5206.38 11530.8 2024/2025 Royal Pharmazone AAW Boots Al Hajerey 63083.88 31813.599999999999 24360.3 3342.1 13295.79.
Scene 21 (5m 31s)
YTD-2025/2026 Performance Summary Per SKU Value. 21.
Scene 22 (5m 53s)
YTD-2025/2026 Performance Summary Per SKU Value. 22.
Scene 23 (6m 13s)
YTD-2025/2026 Performance Summary Per SKU Value. 23.
Scene 24 (6m 33s)
YTD-2025/2026 Performance Summary Per SKU Value. 24.
Scene 25 (6m 51s)
YTD-2025/2026 Performance Summary Per SKU Value. 25.
Scene 26 (7m 11s)
Strengths Well Known brands Weaknesses Low bonus Threats Cancelation of afia which cause low flow of patient in private sector opportunities Penetrate accounts with new products High quality products Good experience with doctors and patient High clinical evidence for efficacy and safety low price specially in the cough range Sponsor some ads targeting group of end users specially bronchicum Availability in the most of the accounts the increase the flow specially in KOC Narrow SKUs Range Had many products for certain specialty or indication Seasonal indication of the most of the range No leave behind materials to remind the doctors No direct Ads to end users specially for allergy range Some out-of-stock situation with competitors Dar al Shefaa problems Corruption in intranasal corticosteroid as Mometix and palmon as anti-histamine gener.
Scene 27 (7m 46s)
Penetrate KOC with Mucosulvan LA & Enterogemina Vail Increase the rate of Enterogermina in Kuwait hospital Increase rate of the bronchicum in Alia hospital Penetrate Nassem Al Jazzera with Telfast 120 and 180 and Enterogermina Hold meeting for ER department in Taiba Hold meeting for ER department in KOC More focus on derma doctors specially in private.
Scene 28 (8m 3s)
Desma.
Scene 29 (8m 15s)
YTD-2025/2026 Performance Summary. 29. YTD Budget 25/26 YTD Achievement 25/26 LY Achievement 24/25 % Vs Target Variance Vs Target Total Line 10032 7038.36 9265.28 70.2% -2993.64.
Scene 30 (8m 35s)
Thank You.